MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Authors

+14 authors

Journal

Published

Nov 5, 2024

DOI

Save

Tip

Document

Download

Flag content

Tip

Save

Document

Download

Flag content

Abstract

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.